Erasca (ERAS) Net Cash Flow (2020 - 2026)
Erasca posted quarterly Net Cash Flow of -$26.5 million for Q1 2026, down 1067.88% year-on-year from $2.7 million in Q1 2025, and down 842.63% on a QoQ basis from $3.6 million in Q4 2025.
Erasca (ERAS) has 7 years of Net Cash Flow data on file, last reported at -$26.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow fell 1067.88% year-over-year to -$26.5 million; the trailing twelve-month figure through Mar 2026 stood at -$23.2 million (down 271.97% YoY), and the FY2025 full-year result was $6.1 million, up 123.94% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$26.5 million, down from $3.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $96.1 million in Q2 2024 and bottomed at -$134.0 million in Q2 2023.
- The 5-year median for Net Cash Flow is -$16.3 million (2024), against an average of -$18.4 million.
- The widest annual swing landed in 2025, when Net Cash Flow soared 411.95%; it then slumped 1067.88% in 2026.
- A 5-year view of Net Cash Flow shows it stood at $65.0 million in 2022, then sank by 130.46% to -$19.8 million in 2023, then surged by 94.21% to -$1.1 million in 2024, then jumped by 411.95% to $3.6 million in 2025, then tumbled by 842.63% to -$26.5 million in 2026.
- The last three Net Cash Flow figures came in at -$26.5 million (Q1 2026), $3.6 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -26.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.55 Mn |
| Mar 31, 2026 | -26.55 Mn |
| Dec 31, 2025 | 3.58 Mn |
| Dec 31, 2025 | 3.58 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | -4.34 Mn |
| Jun 30, 2025 | -4.34 Mn |
| Mar 31, 2025 | 2.74 Mn |
| Mar 31, 2025 | 2.74 Mn |
| Dec 31, 2024 | -1.15 Mn |
| Dec 31, 2024 | -1.15 Mn |
| Sep 30, 2024 | -103.92 Mn |
| Sep 30, 2024 | -103.92 Mn |
| Jun 30, 2024 | 96.08 Mn |
| Jun 30, 2024 | 96.08 Mn |
| Mar 31, 2024 | -16.35 Mn |
| Mar 31, 2024 | -16.35 Mn |
| Dec 31, 2023 | -19.79 Mn |
| Dec 31, 2023 | -19.79 Mn |
| Sep 30, 2023 | -25.93 Mn |
| Sep 30, 2023 | -25.93 Mn |
| Jun 30, 2023 | -133.97 Mn |
| Jun 30, 2023 | -133.97 Mn |
| Mar 31, 2023 | -11.46 Mn |
| Mar 31, 2023 | -11.46 Mn |
| Dec 31, 2022 | 64.96 Mn |
| Dec 31, 2022 | 64.96 Mn |
| Sep 30, 2022 | -78.75 Mn |
| Sep 30, 2022 | -78.75 Mn |
| Jun 30, 2022 | -35.34 Mn |
| Jun 30, 2022 | -35.34 Mn |
| Mar 31, 2022 | -27.14 Mn |
| Mar 31, 2022 | -27.14 Mn |
| Dec 31, 2021 | -85.32 Mn |
| Dec 31, 2021 | -85.32 Mn |
| Sep 30, 2021 | 289.42 Mn |
| Sep 30, 2021 | 289.42 Mn |
| Jun 30, 2021 | -13.59 Mn |
| Jun 30, 2021 | -13.59 Mn |
| Mar 31, 2021 | 104.71 Mn |
| Mar 31, 2021 | 104.71 Mn |
| Dec 31, 2020 | 3.36 Mn |
| Dec 31, 2020 | 3.36 Mn |
| Sep 30, 2020 | -42.01 Mn |
| Sep 30, 2020 | -42.01 Mn |